J&J to pay $2.2bn in 'shameful' US fraud case
This article was originally published in SRA
Executive Summary
Johnson & Johnson and its subsidiaries have found out the hard way that the US Food and Drug Administration is dead serious when it warns drug makers against ignoring its regulatory authority.